Moving from ignorance on the complexity of HDL to novel therapeutic opportunities - PACE-CME

Moving from ignorance on the complexity of HDL to novel therapeutic opportunities

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Positive phase II trial data with novel anti-PCSK9 agent
Positive phase II trial data with novel anti-PCSK9 agent
EAS 2019
Positive phase II trial data with novel anti-PCSK9 agent
- Evan Stein, MD, PhD
Efforts to move universal cholesterol screening before the age of 20 forward
Efforts to move universal cholesterol screening before the age of 20 forward
EAS 2019
Efforts to move universal cholesterol screening before the age of 20 forward
- Professor Kausik Ray, MD
Genetic variants and elevated risk of CAD
Genetic variants and elevated risk of CAD
EAS 2019
Genetic variants and elevated risk of CAD
- Heribert Schunkert, MD
More intelligent intervention through more strategic use of CV biomarkers
More intelligent intervention through more strategic use of CV biomarkers
EAS 2019
More intelligent intervention through more strategic use of CV biomarkers